Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) EBT (2021 - 2025)

Senti Biosciences has reported EBT over the past 5 years, most recently at -$18.5 million for Q4 2025.

  • Quarterly results put EBT at -$18.5 million for Q4 2025, down 16.33% from a year ago — trailing twelve months through Dec 2025 was -$67.9 million (down 12.91% YoY), and the annual figure for FY2025 was -$67.9 million, down 12.92%.
  • EBT for Q4 2025 was -$18.5 million at Senti Biosciences, down from -$16.8 million in the prior quarter.
  • Over the last five years, EBT for SNTI hit a ceiling of -$1178.0 in Q1 2021 and a floor of -$43.3 million in Q3 2023.
  • Median EBT over the past 5 years was -$15.4 million (2022), compared with a mean of -$15.3 million.
  • Biggest five-year swings in EBT: crashed 997692.87% in 2022 and later skyrocketed 65.2% in 2024.
  • Senti Biosciences' EBT stood at -$3.9 million in 2021, then plummeted by 306.16% to -$15.7 million in 2022, then fell by 16.63% to -$18.3 million in 2023, then increased by 12.78% to -$15.9 million in 2024, then dropped by 16.33% to -$18.5 million in 2025.
  • The last three reported values for EBT were -$18.5 million (Q4 2025), -$16.8 million (Q3 2025), and -$16.5 million (Q2 2025) per Business Quant data.